Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences
27. Dezember 2021 17:17 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results
11. November 2021 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022 Received Investigational New Drug (“IND”) clearance from the FDA for AT-1501 in islet cell transplantation in the U.S. ...
Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021
04. November 2021 17:34 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Announces Participation in November Conferences
04. November 2021 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021
01. November 2021 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...
Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium
07. Oktober 2021 07:51 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress
05. Oktober 2021 16:22 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Present at Two Investor Conferences in September
01. September 2021 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
12. August 2021 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022 Reached agreement with...
Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
02. August 2021 08:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...